1-3 of 3
Debbie Haynes
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Free
Emma Searle, Victoria Campbell, Charlotte Pawlyn, Ceri Bygrave, Sarah Gooding, James Cavet, Matthew W. Jenner, Vivek Radhakrishnan, Steve Knapper, Dima el-Sharkawi, Jenny O'Nions, Tomasz Knurowski, Karen Clegg, Will Henry West, Debbie Haynes, Kris Frese, Tim Somervaille
Journal: Blood
Blood (2024) 144 (Supplement 1): 1023.
https://doi.org/10.1182/blood-2024-199779
Published: 2024
Journal Articles

Tolerability and Clinical Activity of Novel First in Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Free
Emma Searle, James Cavet, Victoria Campbell, Steve Knapper, Ceri Bygrave, Dima El-Sharkawi, Charlotte Pawlyn, Maria Creignou, Harriet Walter, David Valcárcel, Marta Hidalgo Soto, Jenny O'Nions, Amrutha Sridhar, Tomasz Knurowski, Karen Clegg, Neil Pegg, Will Henry West, Debbie Haynes, Kris Frese, Tim Somervaille
Journal: Blood
Blood (2023) 142 (Supplement 1): 2005.
https://doi.org/10.1182/blood-2023-174652
Published: 2023
Journal Articles

Preclinical and Early Clinical Results Indicate a Role for the Oral p300/CBP Inhibitor Inobrodib (CCS1477) in T-Cell Lymphoma

Free
Victoria Campbell, Harriet Walter, Adam Gibb, Andrew S. Davies, Nagah Elmusharaf, Neil Pegg, Will Henry West, Tomasz Knurowski, Kris Frese, Debbie Haynes, Karen Clegg, Tim Somervaille
Journal: Blood
Blood (2023) 142 (Supplement 1): 5795.
https://doi.org/10.1182/blood-2023-187378
Published: 2023